Journal
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
Volume 12, Issue 5, Pages 728-737Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.cgh.2013.06.024
Keywords
DAA; NS3/4A Protease Inhibitor; Nucleoside/Nucleotide; Non-nucleoside
Categories
Funding
- Merit Review grant from the Veterans Affairs [BX000159]
- Doriann Foundation for hepatitis research, University of Iowa
- NIH [DK78772, DA33541]
- NIH/NCATS Clinical and Translational Science Award [UL1 R000064]
- [K24 DK070528]
Ask authors/readers for more resources
Chronic infection with hepatitis C virus (HCV) is a major global health problem; there are approximately 120 to 130 million chronic infections worldwide. Since the discovery of HCV 24 years ago, there has been a relentless effort to develop successful antiviral therapies. Studies of interferon-alpha-based therapies have helped define treatment parameters, and these treatment strategies have cured a substantial percentage of patients. However, interferon-alpha must be injected; there are problems with tolerability, adherence, and incomplete response in a large percentage of patients. New drug candidates designed to target the virus or the host have recently been introduced at an unprecedented pace. In phase I-III studies, these agents have exceeded expectations and achieved rates of response previously not thought possible. We are, therefore, entering a new era of therapy for HCV infection and interferon independence.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available